Small interfering RNA targeting receptor for advanced glycation end products protects the rats from multibacterial...

Area of Science:

• Biomedical Research
• Molecular Biology
• Immunology

Background:

• Sepsis presents a significant clinical challenge with limited therapeutic options.
• The receptor for advanced glycation end products (RAGE) is emerging as a promising therapeutic target for sepsis.
• RAGE plays a critical role in the inflammatory response during sepsis.

Purpose of the Study:

• To evaluate the efficacy of small interfering RNA (siRNA) targeting RAGE in a rat model of polymicrobial sepsis.
• To investigate the impact of RAGE inhibition on sepsis outcomes, including survival and inflammatory markers.
• To assess the feasibility of using a vector-based siRNA system for RAGE targeting in vivo.

Main Methods:

• Construction of a vector-based RAGE-targeted siRNA expression system (Psilencer-siRNA).
• Intravenous administration of Psilencer-siRNA in rats following cecal ligation and puncture (CLP) to induce sepsis.
• Quantification of RAGE expression in liver tissue, assessment of survival rates, and measurement of plasma cytokine levels.

Main Results:

• Psilencer-siRNA effectively reduced RAGE expression in the liver, which was elevated post-CLP.
• Rats treated with Psilencer-siRNA exhibited significantly improved survival rates compared to control groups (p < 0.05).
• Plasma cytokine levels were markedly decreased in the Psilencer-siRNA treated group (p < 0.001).

Conclusions:

• Targeting RAGE with siRNA demonstrates potential to attenuate hyperinflammation in sepsis.
• RAGE inhibition via siRNA may improve survival outcomes in sepsis patients.
• siRNA-mediated RAGE targeting represents a novel therapeutic strategy for sepsis management.